Navigation Links
New Therapy by Merck is Positioned to Earn Gold-Standard Status by 2011 in the Treatment of Chemotherapy-Induced Nausea and Vomiting

Emerging Agent GlaxoSmithKline's Rezonic Demonstrating Efficacy for Delayed Chemotherapy-Induced Nausea and Vomiting, According to a New Report from

Decision Resources

WALTHAM, Mass., April 9, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the regimen of Merck's Emend for Injection/Ivemend combined with 5-HT3 RA, is positioned to earn gold-standard status in the treatment of chemotherapy-induced nausea and vomiting by 2011. The regimen of Emend for Injection/Ivemend and 5-HT3 RA offers robust efficacy and key advantages in delivery as a result of its availability in a single-dose IV formulation that is more convenient than the three-consecutive-day-dosing schedule of Merck's Emend, the current gold standard.

The new report entitled Chemotherapy-Induced Nausea and Vomiting: Physician Satisfaction with Inexpensive Antiemetics Sets High Hurdles for Reformulations and Emerging Agents, also finds that GlaxoSmithKline's Rezonic, launching in 2009 as the second-to-market NK1 RA, is positioned as the only emerging agent, compared with Emend, with the potential to demonstrate better control over delayed chemotherapy-induced nausea and vomiting in patients taking highly emetogenic chemotherapy. Preliminary data from clinical trials show that the addition of oral Rezonic to GlaxoSmithKline's Zofran and Merck/Banyu's Decadron result in an 86 percent of patients with no emetic episodes and do not require rescue therapy compared with Emend's 68 percent; however, more data is needed to confirm the effect on delayed chemotherapy-induced nausea and vomiting. Additionally, unless Rezonic shows extraordinary efficacy or is priced much lower than currently available NK1 antagonists, it is not expected to gain more patient share than the Emend franchise owing to Emend's first-to-market status in the injectable NK1 antagonist class.

"Even if Rezonic meets the challenge in reducing chemotherapy-induced nausea and vomiting, it will face stiff competition from Emend and Emend for Injection/Ivemend as a result of these agents' earlier launches and lower prices," said Nancy Li, analyst at Decision Resources. "In an increasingly budget-conscious healthcare environment, payers may not be willing to reimburse a premium for small improvements in efficacy, safety, tolerability and delivery."

About the Report

Chemotherapy-Induced Nausea and Vomiting: Physician Satisfaction with Inexpensive Antiemetics Sets High Hurdles for Reformulations and Emerging Agents is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (, is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources


SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
3. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
4. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
5. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
6. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
7. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
8. Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO
9. Stem Cell Therapy to Skyrocket by 2017
10. Team demos safety of RNA therapy
11. First European IGRT School Takes Place for Radiotherapy Practitioners in UK
Post Your Comments:
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - ... "Company") announced today that the remaining 11,000 post-share ... Share Purchase Warrants (the "Series B Warrants") subject ... were exercised on November 23, 2015, which will ... Shares.  After giving effect to the issuance of ...
(Date:11/24/2015)... ... , ... InSphero AG, the leading supplier of easy-to-use solutions for production, culture, ... serve as Chief Operating Officer. , Having joined InSphero in November 2013 ... was promoted to Head of InSphero Diagnostics in 2014. There she has built ...
(Date:11/24/2015)... Capricor Therapeutics, Inc. (NASDAQ: ... development and commercialization of first-in-class therapeutics, today announced that ... scheduled to present at the 2015 Piper Jaffray Healthcare ... at The Lotte New York Palace Hotel in ... . --> . ...
(Date:11/24/2015)... MUNICH and NEW YORK , ... irst investment by Bristol-Myers Squibb in a ... Bristol-Myers Squibb Company in which the companies ... products in immuno-oncology and other areas of unmet medical need. ... Squibb in LSP 5, the latest LSP fund. This is ...
Breaking Biology Technology:
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... 29, 2015 Daon, a global leader in ... released a new version of its IdentityX Platform ... North America have already installed IdentityX v4.0 ... a FIDO UAF certified server component as ... activate FIDO features. These customers include some of the ...
(Date:10/29/2015)... , October 29, 2015 ... biometric authentication company focused on the growing mobile ... wallet announces that StackCommerce, a leading marketplace to ... featuring the Wocket® smart wallet on StackSocial for ... ) ("NXT-ID" or the "Company"), a biometric authentication ...
Breaking Biology News(10 mins):